News Release

Hemoglobin Removal Whitepaper Describes a Range of Depletion Strategies and Their Successful Uses

MONMOUTH JUNCTION, NJ, May 8, 2020 -- Biotech Support Group reports on a Whitepaper describing the simplicity and efficiency of their hemoglobin depletion technology in a diverse range of applications including the annotation of the red cell proteome, the identification of drug-target interactions, and the removal of a variety of analytical interferences.

The Whitepaper is entitled:

“Hemoglobin Removal - The Gold Standard Products”, April 28, 2020

Hemoglobin accounts for ≥ 95% of the protein mass in erythrocytes, and is often an interfering factor for many types of analysis, both proteinaceous (i.e., immunoassay) and non-proteinaceous (i.e., PCR). With the rising use of dried blood cards and point-of-care devices, analytical interferences from Hemoglobin continues to present problems. BSG products offer a simple and efficient solution for Hemoglobin removal in a variety of separation strategies and formats. Out of the 40+ citations for these products, the Whitepaper highlights some of the more definitive examples of how Hemoglobin depletion improved the value of the research investigation. Successful uses are described for diseases such as Malaria and Parkinson's Disease, as well as drug-target interactions and post-translational modifications discovered from erythrocyte proteomes. Sample types include erythrocyte lysates, hemolyzed serum, whole blood, and dried blood cards. The BSG application specific products are especially designed for all these challenges. 

“We now know that red cells carry more than just oxygen, and cooperate in some way with the other blood compartments. With the efficiency of Hemoglobin removal that our products provide, investigators can now study the many aspects of red cells as they relate to disease. Finally, we can provide a simple method to remove Hemoglobin interference, as this can often be a problem with more routine clinical analysis. This is becoming especially important with the growing use of dried blood cards and point-of-care devices”, states Swapan Roy, Ph.D., President and Founder of Biotech Support Group. 

For more information on all of our Hemoglobin removal products, visit: https://www.biotechsupportgroup.com/Articles.asp?ID=452

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, and HemogloBind™ and HemoVoid™ for hemoglobin removal. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com

For Business Development, Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com